AI & Multi-omics – Shifting Paradigms in the New Era of Early Cancer Detection and Precision Oncology
An academic event in Danang, Vietnam, to foster collaboration and knowledge sharing among oncologists in the Asia-Pacific region.
2026
EXPERTS MEETING
| K-CONNECT SUMMIT 2026
K-CONNECT SUMMIT 2026 is a high-level scientific forum taking place from 8–10 May 2026 at Melia Danang Beach Resort, bringing together regional and international experts in precision oncology. Under the theme “AI & Multi-omics – Shifting Paradigms in the New Era of Early Cancer Detection and Precision Oncology”, the summit focuses on translating ctDNA, MRD, multi-omics, AI integration, and comprehensive genomic profiling into real-world clinical practice across Asia-Pacific.
2025
EXPERTS MEETING
| K-CONNECT APAC 2025
An exclusive event in Danang, Vietnam, bringing together leading oncologists and researchers from across the Asia Pacific region K-CONNCECT APAC 2025 aims to delve into the cutting-edge applications of ctDNA-MRD, share real-world experiences, and collaborate on pioneering advancements in precision oncology.
The event will feature over 100 invited oncologists as speakers and delegates, hosted by Gene Solutions.
CLINICAL TRIAL SUPPORT
| A COLLABORATIVE EFFORT TO ADVANCE CANCER CARE
The K-CONNECT Platform, in collaboration with local partners and Biopharma companies, offers oncologist access to a complimentary first K-TRACK test, or Applicants for supported diagnostics assays in clinical research. This initiative underscores our commitment to advancing precision oncology and improving patient outcomes.
EXPERIENCE MRD
| LEADING THE FUTURE OF PRECISION ONCOLOGY
Join leading oncologists across Asia in transforming cancer care through cutting-edge ctDNA-MRD technology.
Oncologists can easily access this offer through the K-CONNECT Platform. Simply log in to your account and follow the designated pathway. Our user-friendly interface will guide you through the process, ensuring a seamless experience.
WEBINARS
A series of webinars for knowledge sharing, covering the latest advancements in cancer treatment and emerging technologies in precision medicine.
Speakers:
Le Thuong Vu
University Medical Center, Ho Chi Minh City
Speakers:
Sutima Luangdilok
Chulalongkorn University, Thailand
Speakers:
Sita Laksmi Andarini
National Referral for Repiratory diseases, RSUP Persahabatan
Speakers:
Pornchai O-Charoenrat
Chaophya Hospital, Thailand
Speakers:
Samuel Haryono
Siloam MRCCC, Jakarta, Indonesia
Speakers:
Nick Pavlakis
University of Sydney, Australia
Speakers:
Le Son Tran
Medical Genetics Institute, Vietnam
Speakers:
Aaron Tan Chia-Ken
National Cancer Centre Singapore
Speakers:
Herbert Ho Fung Loong
The Chinese University of Hong Kong
Speakers:
Panel discussion and Q&A
Bridging the gap in genomic insights across the Asia-Pacific region
Speakers:
Nguyen Luu Hong Dang
Medical Genetics Institute, Vietnam
Speakers:
Nick Pavlakis
University of Sydney, Australia
CASE STUDIES
Source:
JCO Oncology Advances
Cancer type:
Lung Cancer
- To protect patient confidentiality, all names and images mentioned have been changed
Source:
JCO Oncology Advances
Cancer type:
Lung Cancer
- To protect patient confidentiality, all names and images mentioned have been changed
Source:
JCO Oncology Advances
Cancer type:
Lung Cancer
- To protect patient confidentiality, all names and images mentioned have been changed
Source:
JCO Oncology Advances
Cancer type:
Lung Cancer
- To protect patient confidentiality, all names and images mentioned have been changed
Source:
JCO Oncology Advances
Cancer type:
Colorectal Cancer
- To protect patient confidentiality, all names and images mentioned have been changed
Source:
JCO Oncology Advances
Cancer type:
Breast Cancer
- To protect patient confidentiality, all names and images mentioned have been changed
PUBLICATIONS
ctDNA Monitoring to Predict the Efficacy of TNT for Rectal Cancer
Publisher:
clinicaltrials.gov
Publication date:
September 16, 2023
Key finding:
This is a prospective observational study, in collaboration with 3 hospitals (175 Military Hospital, Nguyen Tri Phuong Hospital, and 108 Military Central Hospital), plans to recruit 100 patients with stage II-III rectal cancer and indicated for total neoadjuvant therapy. K-TRACK assay will use to evaluate value of ctDNA in Predict the Efficacy of TNT for Rectal Cancer.
Investigate the Prognostic and Predictive Value of ctDNA During Neoadjuvant Chemotherapy for Breast Cancer
Publisher:
clinicaltrials.gov
Publication date:
October 18, 2023
Key finding:
This prospective and observational study, in collaboration with University Medical Center HCMC, plans to recruit 75 patients with stage II-III HER+/Triple Negative Breast cancer and indicated for neoadjuvant chemotherapy. K-TRACK assay will use aim to determine the detection rate and change of ctDNA in blood samples of cancer patients before, during and after neoadjuvant treatment.
SPEAKERS & PANELISTS
Associate Professor
